Non-melanoma skin cancers: Biological and clinical features
M Cives, F Mannavola, L Lospalluti, MC Sergi… - International Journal of …, 2020 - mdpi.com
Non-melanoma skin cancers (NMSCs) include basal cell carcinoma (BCC), squamous cell
carcinoma (SCC) and Merkel cell carcinoma (MCC). These neoplasms are highly diverse in …
carcinoma (SCC) and Merkel cell carcinoma (MCC). These neoplasms are highly diverse in …
Roles of the RANKL–RANK axis in antitumour immunity—implications for therapy
Recognizing that the transformative effects of immunotherapy are currently limited to a
minority of patients with cancer, research efforts are increasingly focused on expanding and …
minority of patients with cancer, research efforts are increasingly focused on expanding and …
Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy
PURPOSE Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the
Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for …
Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for …
Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial
SP D'Angelo, J Russell, C Lebbé, B Chmielowski… - JAMA …, 2018 - jamanetwork.com
Importance Merkel cell carcinoma (MCC) is an aggressive skin cancer that is associated
with poor survival outcomes in patients with distant metastatic disease. Results of part A of …
with poor survival outcomes in patients with distant metastatic disease. Results of part A of …
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical …
HL Kaufman, JS Russell, O Hamid, S Bhatia… - … for immunotherapy of …, 2018 - Springer
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial …
poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial …
[HTML][HTML] Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN …
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
Merkel cell carcinoma, version 1.2018, NCCN clinical practice guidelines in oncology
CK Bichakjian, T Olencki, SZ Aasi, M Alam… - Journal of the National …, 2018 - jnccn.org
This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on
areas impacted by recently emerging data, including sections describing MCC risk factors …
areas impacted by recently emerging data, including sections describing MCC risk factors …
[HTML][HTML] First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II …
Background Avelumab (anti-programmed death ligand 1 (PD-L1)) is approved in multiple
countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and …
countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and …
Merkel cell carcinoma in the age of immunotherapy: facts and hopes
Merkel cell carcinoma (MCC) is a rare (∼ 2,000 US cases/year) but aggressive
neuroendocrine tumor of the skin. For advanced MCC, cytotoxic chemotherapy only …
neuroendocrine tumor of the skin. For advanced MCC, cytotoxic chemotherapy only …
[HTML][HTML] Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
JW Walker, C Lebbé, G Grignani, P Nathan… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Avelumab, a human anti–programmed death-ligand 1 immunoglobulin G1
monoclonal antibody, showed favorable efficacy and safety in patients with metastatic …
monoclonal antibody, showed favorable efficacy and safety in patients with metastatic …